Chandigarh Herald

Gastric Neuroendocrine Tumors Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2022-2032), States DelveInsight | Key Companies – Pharmathene Ltd, GSK

 Breaking News
  • No posts were found

Gastric Neuroendocrine Tumors Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2022-2032), States DelveInsight | Key Companies – Pharmathene Ltd, GSK

April 06
17:11 2023
 Gastric Neuroendocrine Tumors Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2022-2032), States DelveInsight | Key Companies - Pharmathene Ltd, GSK
DelveInsight Business Research LLP
DelveInsight’s “Gastric Neuroendocrine Tumors Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Gastric Neuroendocrine Tumors, historical and forecasted epidemiology as well as the Gastric Neuroendocrine Tumors market trends in the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

DelveInsight’s “Gastric Neuroendocrine Tumors Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Gastric Neuroendocrine Tumors, historical and forecasted epidemiology as well as the Gastric Neuroendocrine Tumors market trends in the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Gastric Neuroendocrine Tumours Overview

Gastric Neuroendocrine Tumors are rare lesions characterized by hypergastrinemia that arise from enterochromaffin-like cells of the stomach. GNETs consist of a heterogeneous group of neoplasms comprising tumor types of varying pathogenesis, histomorphologic characteristics, and biological behavior.

Gastric Neuroendocrine Tumours Epidemiology Insights

  • The incidence rates of GEP NECs increased consistently from 1.5 cases per 1,000,000 in 1973 to 4.6 cases per 1,000,000.

  • 34% of cases were small cell carcinomas. Certain primary tumor sites such as the anus and esophagus were more predominantly small cell histology.

  • The presence of metastatic disease at diagnosis ranged from 40 to 76%, with pancreatic NECs most likely to present with metastatic disease.

Click here to learn more about the Gastric Neuroendocrine Tumours Market Landscape

The Report Covers the Gastric Neuroendocrine Tumours Epidemiology Segmented by:

  • Gastric Neuroendocrine Tumours incident cases 

  • Gastric Neuroendocrine Tumours diagnosed cases 

  • Gastric Neuroendocrine Tumours treatment cases 

  • Gastric Neuroendocrine Tumours prevelant cases 

Gastric Neuroendocrine Tumours Market Outlook 

The Gastric Neuroendocrine Tumors market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Gastric Neuroendocrine Tumors market trends by analyzing the impact of current Gastric Neuroendocrine Tumors therapies on the market, unmet needs, drivers and barriers, and demand for better technology. 

This segment gives a thorough detail of the Gastric Neuroendocrine Tumors market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Gastric Neuroendocrine Tumors market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Gastric Neuroendocrine Tumors market in 7MM is expected to witness a major change in the study period 2019-2032.

 Key Companies Working in the Gastric Neuroendocrine Tumours Market

  • Novartis 

  • Ipsen 

  • PharmaMar 

  • TiRex Inc 

  • RayZe Bio Inc 

  • Pfizer 

And many others 

Gastric Neuroendocrine Tumours Therapies Covered and Analyzed in the Report:

  • Ribociclib

  • Satoreotide trizoxetan 

  • Octreotide LAR

  • Lanreotide ATG

  • Octreotide LAR

  •  Lutathera

  • Temozolomide

And many others

Learn more about the Key Companies and Emerging Therapies in the Gastric Neuroendocrine Tumours Market

 Table of Contents 

  1. Key Insights 

  2. Gastric Neuroendocrine Tumours Introduction 

  3. Executive Summary of Gastric Neuroendocrine Tumours  

  4. Disease Background and Overview

  5. Epidemiology and patient population

  6. Gastric Neuroendocrine Tumours Emerging Therapies

  7. Gastric Neuroendocrine Tumours Market Outlook

  8. Market Access and Reimbursement of Therapies

  9. Market Drivers 

  10. Market Barriers 

  11. Appendix

  12. Report Methodology

  13. DelveInsight Capabilities

  14. Disclaimer

Learn about the detailed offerings of the report @ Gastric Neuroendocrine Tumours Market Outlook 

Related Reports 

Gastric Neuroendocrine Tumours Pipeline Insights

“Gastric Neuroendocrine Tumours – Pipeline Insight, 2023” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in the Gastric Neuroendocrine Tumours pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products by stage, route of administration, and molecule type. 

Trending Reports by DelveInsight

  • Adalimumab Biosimilar Market

  • Arbovirus Infection Market

  • Artificial Pancreas Device System Market

  • Dental Equipment Market

  • Gluten Sensitivity Market

  • Hypothyroidism Market

  • Inflammatory Bowel Disease Market

  • Mayus Kinase Jak Inhibitors Market

  • Mild Dry Eye Market

  • Mucopolysaccharidosis Market

  • Oncolytic Virus Cancer Therapy Market

  • Pyoderma Gangrenosum Market

  • Transdermal Drug Delivery Devices Market

  • Intrathecal Pumps Market

  • Hedgehog Pathway Inhibitors Market

  • Yellow Fever Market

  • Laryngeal Cancer Market

  • Female Infertility Market

  • Gender Dysphoria Market

  • Chronic Brain Damage Market

  • Spain Healthcare Outlook Market

  • Malignant Fibrous Histiocytoma Market

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services